{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-26-000037","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.514102+00:00","generated_at":"2026-05-14T23:54:29.306490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M","bullets":["Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).","DSPS revenue $53.3M (+28% YoY); NGS revenue $57.4M (+12% YoY).","Net loss $44M ($0.71/share) vs $39.3M ($0.66/share) YoY; adjusted EBITDA loss improved to $13.3M from $14.8M.","Raised FY2026 revenue guidance to $442-447M; reiterates Q4 FY26 adjusted EBITDA breakeven.","Booked $7.2M litigation settlement cost for securities class action; entered bispecific licensing with Invenra."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-26-000037","json":"https://secwatch.observer/filing/0001581280-26-000037.json","markdown":"https://secwatch.observer/filing/0001581280-26-000037.md","text":"https://secwatch.observer/filing/0001581280-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/0001581280-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/twist-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:54:29.306490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0fe18472df0afca1aa065a5843b67fabba5e2e5","claim":"Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.","evidence_excerpt":"expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/0001581280-26-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter 2026"},{"label":"Revenue","value":"$110.7 million"},{"label":"Net income","value":"$44.0 million"},{"label":"EPS","value":"$0.71 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}